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Introduction: The optimal treatment for patients older than 80
years with small cell lung cancer (SCLC) is unknown.
Methods: A retrospective chart review was conducted for 45
patients aged 80 years or older with SCLC, and therapeutic
indices and toxicities of anticancer treatment were compared with
those of 38 patients aged 70 to 79 years. Subgroup analyses
according to the levels of performance status (PS) and comor-
bidity were also performed.
Results: Twenty-four (53%) of the 45 patients underwent com-
bination chemotherapy and/or thoracic radiotherapy, which re-
sulted in significant survival benefit compared with those left
untreated (p  0.01). The main reasons for not administrating
anticancer treatments were advanced age (85 years), poor PS,
and severe comorbidities. The average total chemotherapy dose
delivered was 60% of the intended protocol dose. Median sur-
vival time and 1-year survival of the treated patients were 13.0
months and 57% for limited disease and 10.3 months and 40% for
extensive disease, respectively. Despite a lower chemotherapy
dose being administered, survival indices were similar to those of
patients aged 70 to 79 years. Survival benefit was observed even
in the treated patients with PS 2 to 3 or a moderate degree of
comorbidity compared with those left untreated. The frequency
of grade 3 to 4 hematologic toxicities was not significantly
different between the two age groups.
Conclusions: The standard chemotherapy regimen with or with-
out thoracic radiotherapy seems to be feasible for patients older
than 80 years with SCLC, even for those with PS 2 to 3 and/or
moderate comorbidity, although frequent dose adjustment is
necessary.
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Small cell lung cancer (SCLC) accounts for approxi-mately 15% of primary lung cancers.1 Approximately
42% of SCLC cases are diagnosed in patients older than 70
years, and 10% are diagnosed in patients older than 80
years.1,2 Because of its rapid doubling time, high growth
fraction, and high sensitivity to chemotherapy and radio-
therapy, anticancer treatments (chemotherapy and/or tho-
racic radiotherapy [TRT]) for SCLC are recommended
even for patients older than 70 years or those with rela-
tively poor performance status (PS).3–5 However, elderly
patients are usually excluded from prospective chemother-
apy trials for SCLC, either because of age alone or because
of the presence of a comorbid illness that renders them
ineligible. Recently, several phase II studies of combina-
tion chemotherapy and TRT in elderly patients aged 70
years or older were reported and suggested that these
treatments result in significant survival improvements in
elderly patients with SCLC.6–10 However, these studies
rarely included patients older than 80 years; thus, the
optimal treatment for patients older than 80 years with
SCLC is still unknown. Most physicians may be aware that
biological age instead of chronological age should be
considered when elderly patients with SCLC receive anti-
cancer treatment; however, these patients are still at risk
for being undertreated because of age-related progressive
reductions in organ function and comorbidities.3–5 In cur-
rent practice, patients older than 80 years with SCLC
usually receive untested or inadequate treatment based on
the extrapolated results of randomized control trials
(RCTs) for younger patients. Furthermore, it is uncertain
whether patients older than 80 years with SCLC with poor
PS or significant comorbidities exhibit improved survival
by anticancer treatments.
To assess the efficacy and safety of anticancer treat-
ment for very old patients with SCLC, we compared
response rate, survival, and adverse events between pa-
tients aged 70 to 79 years with SCLC who underwent
anticancer treatment and those aged 80 years or older.
METHODS
Study Population
We conducted a retrospective analysis of all consec-
utive patients admitted to our department for SCLC from
Division of Respiratory Medicine, Tokyo Metropolitan Geriatric Hospital,
Tokyo, Japan.
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January 1996 to March 2007. We identified patients who
had histologic or cytologic confirmation of SCLC using a
database of pathologic records at our hospital. The initia-
tion of the study period roughly corresponded to the time
when the conventional approach for chemotherapy for
SCLC changed from a combination of cyclophosphamide,
adriamycin, and vincristine (CAV) to that of carboplatin
and etoposide (cPE) in the hospital. Patients aged 70 years
or older with no previous chemotherapy or radiotherapy
for SCLC were eligible for the study. We obtained ap-
proval from our hospital for use of patient records for our
study, and patient confidentiality was maintained.
Measurements
A retrospective chart review was performed with
medical history, physical examination, Eastern Coopera-
tive Oncology Group PS, clinical stage according to the
two-stage system of the Veterans Administration Lung
Cancer Group, laboratory and radiologic findings, therapy
administered, adverse events, and clinical outcomes.11,12
The patients were then divided into two age groups: 70 to
79 years and 80 years or older. For subsequent analyses,
the correlation between clinical factors evaluated at the
initial diagnosis, such as age (70–79 years versus 80
years), sex, PS (0–1 versus 2–3), and comorbidity accord-
ing to Charlson index (CI), disease extent (limited disease
[LD] versus extensive disease [ED]), efficacy of first-line
therapy (responders/nonresponders), adverse events, and
survival, were investigated. The CI provides a weighted
index of comorbidity based on relative risks of death
associated with 19 clinical conditions.13 Because SCLC is
a high mortality disease, we set cutoffs of CI 0 to 1 as
“mild,” CI 2 to 3 as “moderate,” and CI 4 or greater (CI
4) as “severe” comorbidities.
Treatment
There were no distinct eligible criteria for anticancer
treatments, and a decision to administer chemotherapy and
TRT was based on the patient’s PS, comorbidity, willing-
ness to undergo therapy, and other conditions such as
cognitive function and social support. As a first-line che-
motherapy, standard treatment (i.e., chemotherapy admin-
istered at the full dose for younger patients with or without
TRT) was performed on patients aged 70 to 74 years with
PS 0 to 1 and normal renal function, whereas low-dose
chemotherapy (60–80% doses of the optimal treatment)
was adopted for most patients older than 75 years or with
PS 2 upon judgment by the physicians in charge. The
first-line chemotherapy regimen in most cases consisted of
cPE or carboplatin plus irinotecan (cP/irinotecan) with
granulocyte colony-stimulating factor support, whereas
CAV was used in some patients in an earlier period of the
study. Because the schedule of treatment was variable in
our patient population, we only compared initial dose
delivery, total dose delivered, dose delivery per cycle, and
dose reductions or omission of the first-line chemotherapy.
Treatment omissions were assessed by calculating the total
number of administrations for each regimen, and dose
reductions were calculated by assessment of total dose
actually delivered compared with the full dose of the
protocol. The full dose of each chemotherapy regimen was
defined as follows: cPE, carboplatin area under the curve
(AUC) 5 on day 1, and etoposide 100 mg/m2 on days 1 to
3; cP/irinotecan, carboplatin AUC 5 on day 1, and irino-
tecan 60 mg/m2 on days 1, 8, and 15; and CAV, cyclo-
phosphamide 1000 mg/m2, doxorubicin 50 mg/m2, and
vincristine 1 mg/m2 on day 1. Each regimen was repeated
every 4 weeks if the patient recovered from all toxicities
related to previous cycles. Treatment modification, such as
dose reduction, dose omission, or schedule delay, was
determined by the physicians in charge. The dose of each
cycle was expressed as a fraction of the actually delivered
dose to the standard treatment dose. The total dose admin-
istered for each regimen was calculated by adding all
cycles of chemotherapy. Finally, the actually delivered
dose of the first-line chemotherapy cycles was compared
with the optimal protocol dose. TRT was delivered at a
single dose of 2 Gy once daily up to a total of 50 Gy
concurrently or 60 Gy sequentially with chemotherapy.
Evaluation
Tumor response to the first-line chemotherapy with
or without TRT was re-evaluated by two physicians (T.N.
and H.T.) in accordance with World Health Organization
criteria.14 All patients were followed up for at least 2 years.
Overall survival was measured from the date of diagnosis
of SCLC to the date of death or the date of the last
follow-up evaluation. Toxicity was graded in accordance
with the National Cancer Institute-Common Toxicity Cri-
teria.15
Statistical Analysis
Numerical data are expressed as means  SEM
unless otherwise indicated. Comparison between each clin-
ical factor and response was performed using the 2 test or
Fisher’s exact test, probability test depending on the num-
ber of patients. Clinical and laboratory data were analyzed
with Student t test for the comparison of continuous
variables. The survival curve was estimated by the Kaplan-
Meier method and compared by the log-rank test. Values
of p  0.05 were considered statistically significant.
RESULTS
Between 1996 and 2007, data on 83 patients aged 70
years or older with SCLC were recorded on the pathologic
database. Thirty-eight (46%) of these patients were aged
70 to 79 years and 45 (54%) were aged 80 years.
Baseline characteristics including sex, body mass index,
smoking history, and comorbidity evaluated by CI and
clinical stage were comparable between the two age
groups, although the proportion of patients with a PS of 2
to 4 was significantly greater in the 80 years group
(Table 1). Thirty-three (87%) of the 38 patients aged 70 to
79 years and 24 (53%) of the 45 patients aged 80 years
underwent chemotherapy and/or TRT for SCLC (p 
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0.001). Among the 45 patients aged 80 years, the treated
patients were significantly younger than those left un-
treated for primary tumor (mean age, 82.7  0.4 years
versus 85.2  0.9 years, p  0.001, respectively). The
main reasons for not administrating anticancer treatments
to patients aged 80 years were advanced age (age 85
years) for six, poor PS (PS 4) for four, severe comorbid
diseases (CI 4) and/or decreased mental activity for four,
patient’s wishes for three, and an unknown reason for four,
whereas the reasons for those aged 70 to 79 years were
severe comorbid diseases for three and poor PS for two
patients.
Overall, there was significantly improved survival
for patients who received anticancer treatment compared
with those left untreated for primary tumor, although there
might be selection issues that inherently give a survival
advantage to the group that was treated (Figure 1). The
survival distributions among treated and untreated patients
were similar for the two age groups. The results suggested
that age did not significantly affect survival among the two
age groups that underwent chemotherapy and/or TRT.
Median survival times (MSTs) for the treated patients aged
70 to 79 years and 80 years were not significantly
different, 11.1 and 13.1 months, respectively. Subgroup
analysis of the patients aged 80 years according to PS
levels is shown in Figure 2. Because all patients aged 80
years with PS 4 were left untreated for primary tumor,
survival was compared between treated and untreated
patients aged 80 years with PS 2 to 3. The survival
distribution was significantly better for patients with PS 0
to 1 than for those with PS 2 to 3 (p  0.01). Among 20
patients aged 80 years with PS 2 to 3, better survival was
observed in the treated patients than in the untreated
TABLE 1. Baseline Characteristics and Treatment of Elderly
Patients with SCLC
70–79 yr 80 yr p
Number 38 45
Age 76.0  0.4 84.0  0.5 0.001
Sex (M/F) 29/9 28/17 0.19
BMI 22.3  0.6 21.2  0.6 0.18
Smoking (pack-yr)a 63.4  6.6 66.8  7.3 0.68
Performance status 0.02
0, 1 29 21
2–3 7 20
4 2 4
Charlson index 0.75
0, 1 21 23
2–3 13 20
4 3 2
Clinical stage 0.84
LD 27 31
ED 11 14
Treated for primary tumor 33 24c 0.001
CT 18 14
CT  TRTb 14 7
TRT 1 3
BSC 5 21c
a All patients were current or exsmokers except for one patient in each group.
b Among patients who underwent a combination of CT and TRT, 4 of 14 patients
aged 70–79 yr and none of the 7 patients aged 80 yr were treated concurrently.
c Mean ages of the 24 treated and 21 untreated patients were 82.7  0.4 yr and
85.2  0.9 yr, respectively (p  0.01).
CI, Charlson index; BMI, body mass index; LD, limited disease; ED, extensive
disease; CT, chemotherapy; TRT, thoracic radiotherapy; BSC, best supportive care.
FIGURE 1. Comparison of survival curves according to the
two independent factors: age (70–79 years versus 80
years) and treatment for primary tumor. The solid thin line
represents the group aged 70 to 79 years with treatment
(TX) (n  33, MST: 11.1 months), the solid bold line that
of patients aged 80 years with treatment (n  24, MST:
13.1 months), the broken thin line that of patients aged 70
to 79 years without treatment (TX) (n  5, MST: 2.1
months), and the broken bold line that of patients aged
80 years without treatment (n  21, MST: 2.5 months).
Survival was significantly longer in treated groups than un-
treated groups regardless of age (p  0.01). MST, median
survival time.
FIGURE 2. Comparison of survival curves of the treated
(TX) and untreated (TX) patients aged 80 years ac-
cording to PS (PS 0–1 versus PS 2–3). The solid thin line
represents the survival curve of the treated patients with PS
0 to 1 (n  17, MST: 20.4 months), the solid bold line that
of treated patients with PS 2 to 3 (n  7, MST: 9.1 months),
the broken thin line that of untreated patients with PS 0 to
1 (n  4, MST: 6.9 months), and the broken bold line that
of untreated patients with PS 2 to 3 (n  13, MST: 1.9
months). Longer survival was observed in patients with bet-
ter PS in the treated patients (p  0.01). MST, median sur-
vival time; PS, performance status.
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patients (MST: 9.1 versus 1.9 months, respectively), al-
though the difference is not significant because of the low
number of patients (p  0.06). However, there was no
significant difference in survival curves between patients
with CI 0 to 1 and 2 to 3 aged 80 years (p  0.09)
(Figure 3). It was also notable that survival improvement
by anticancer treatments remained significant when eval-
uating only the 20 patients aged 80 years with CI 2 to 3
(p  0.01), although there might be the selection bias.
There were no significant differences in survival curves
between treated patients aged 70 to 79 years and those
aged 80 years with PS 0 to 1 or those with PS 2 to 3 (data
not shown).
A comparison of overall response rates (complete
plus partial responses) and survival for the two age groups
is shown in Table 2. More than half of the patients with LD
in both groups responded to the first-line treatments,
whereas only two (29%) of seven patients aged 70 to 79
years and two (33%) of six patients aged 80 years with
ED had a partial response. The disease severity of all the
ED patients aged 80 years and most of those aged 70 to
79 years who did not show a complete or partial response
was kept stable during the course of the first-line chemo-
therapy. MST and 1- and 2-year survival rates of patients
were similar in the two groups regardless of the clinical
stages, although formal statistical evaluations are pre-
cluded by the low number of ED patients. Survival indices
were also significantly better in the treated patients with
LD than in those with ED in both age groups (p  0.01).
A comparison of treatment regimen and actually delivered
doses of first-line chemotherapies received by the 51
patients between the two age groups is shown in Table 3.
Chemotherapy regimen and the proportion of TRT combi-
nation actually delivered were not significantly different
between the two age groups. More than two-thirds of
patients aged 70 to 79 years and most of the patients aged
80 years initiated first-line chemotherapy at a dose
80% of the intended full protocol dose. The main reasons
for dose reduction were low levels of PS, comorbidities,
and age older than 75 years in the 70 to 79 years group,
whereas age per se was the most frequent reason in the
80 years group. About half of the patients completed the
full four treatment cycles in both groups. Patients aged 70
FIGURE 3. Comparison of survival curves of the treated
(TX) and untreated (TX) patients aged 80 years ac-
cording to Charlson index (CI) (CI 0–1 versus CI 2–3). The
solid thin line represents the survival curve of the treated
(TX) patients with CI 0 or 1 (n  14, MST: 13.0 months),
the solid bold line that of the treated patients with CI 2 to 3
(n  10, MST: 11.1 months), the broken thin line that of
untreated (TX) patients with CI 0 to 1 (n  9, MST: 2.9
months), and the broken bold line that of untreated patients
with CI 2 to 3 (n  10, MST: 2.5 months). The treated pa-
tients with CI 2 to 3 survived significantly longer than those
left untreated (p  0.01). MST, median survival time.
TABLE 2. Comparison of Response Rate and Mean Survival
Time for Treated Patients between Age Groups
70–79 yr
(n  33)
80 yr
(n  24) p
Response rate (%)a
LD 15/26 (58%) 11/18 (61%) 0.90
ED 2/7 (29%) 2/6 (33%) 0.80
Median survival time (mo)
LD 13.2 13.0 0.95
ED 9.2 10.3 0.69
1-yr survival (%)
LD 14/26 (54%) 10/18 (55%) 0.49
ED 2/7 (28%) 2/6 (33%) 0.60
2-yr survival (%)
LD 7/26 (27%) 5/18 (28%) 0.90
ED 2/7 (28%) 1/6 (17%) 0.80
a Response rate is defined as a proportion of complete plus partial responses.
LD, limited disease; ED, extensive disease.
TABLE 3. Treatment Modalities of First-Line Chemotherapy
70–79 yr
(n  32)
80 yr
(n  21) p
Regimen 0.44
Carboplatin  etoposidea 25 (11) 14 (5)
Carboplatin  irinotecana 2 (0) 3 (1)
CAVa 4 (3) 4 (1)
Cisplatin  etoposidea 1 (0) 0
Dose of the initial cycle 0.82
1 9 4
0.8–0.9 10 9
0.7–0.79 13 8
Completed cycles 0.86
Cycle 1 4 1
Cycle 2 5 5
Cycle 3 7 4
Cycle 4b 16 11
Total delivered dose (%)c
(% of calculated full dose)
65.4  5.6 60.1  5.5 0.51
a Number of patients who received concurrent or sequential TRT is shown in
parentheses.
b One patient in each group received more than 5 cycles of chemotherapy as
first-line chemotherapy.
c Total dose actually delivered compared with the full dose of the protocol.
Total dose administered for each regimen was calculated by adding all cycles of
chemotherapy.
CAV, combination of doxorubicin, cyclophosphamide, and vincristine.
Noguchi et al. Journal of Thoracic Oncology • Volume 5, Number 7, July 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1084
to 79 years received approximately 65% of the total
planned chemotherapy for younger adults, whereas those
aged 80 years received 60% of the total dose.
Modest number of patients in both age groups had
grade 3 to 4 leukocytopenia and/or neutropenia, whereas
grade 3 leukocytopenia and grade 4 neutropenia tended to
occur more frequently in patients aged 80 years during
the first-line chemotherapy (Table 4). Severe anemia or
thrombocytopenia that required transfusions were rare.
Nonhematologic toxicities such as gastrointestinal prob-
lems equal to or greater than grade 3 rarely occurred in
both groups. There was no significant correlation between
total dose of chemotherapy administered and incidence of
grade 3 to 4 leukocytopenic toxicities in either group (data
not shown). Treatment-related mortality occurred in a
patient aged 73 years with ED.
DISCUSSION
This study retrospectively evaluates the response,
survival, and adverse effects in patients aged 80 years
with SCLC treated at a single institution over a 11-year
period compared with those of patients aged 70 to 79
years. About half of the patients aged 80 years under-
went combined chemotherapy and/or TRT for primary
tumor, and these patients survived significantly longer than
those left untreated, even in patients with PS 2 to 3 or those
with moderate comorbidities. There were no significant
differences in response rate, survival rate, or toxicities
between patients aged 80 years and those aged 70 to 79
years despite a consistently lower chemotherapy dose
delivered to the older patients.
For patients with SCLC eligible for RCT and who
received chemotherapy with or without TRT, overall re-
sponse rates and MST were approximately 80 to 90% and
14 to 20 months for patients with LD and 60 to 70% and
7 to 11 months for those with ED, respectively.16,17 Al-
though elderly patients were underrepresented in most of
the previous RCT for SCLC, several phase II and III trials
in patients older than 70 years suggested that the optimal
strategy for the management of elderly fit patients with
SCLC is platinum-based chemotherapy and TRT for LD and
platinum-based combination chemotherapy for ED.6–10,18
However, patients older than 80 years were seldom in-
cluded in these studies, therefore little data is available for
a consensus on the appropriate treatment for patients in
this age group. There are several retrospective studies on
the treatment of patients aged 80 years or older with
SCLC. Shepherd et al.19 reported on five patients aged
80 years with SCLC who were treated with a reduced
dose of chemotherapy between 1976 and 1994 of which
two (40%) exhibited a response. Yau et al.20 reported that
the MST and 1-year survival of patients aged 80 years
with SCLC were 9 weeks and 0% in 10 patients treated in
1984–1994 and 34 weeks and 30% in 16 patients treated in
1996–2003, respectively. Shimizu et al.21 described an
anecdotal study of concurrent chemoradiotherapy for three
patients older than 80 years with LD-SCLC, all of whom
exhibited a complete response with two patients surviving
more than 5 years. Recently, several prospective studies of
platinum-based combination chemotherapy were con-
ducted on the elderly, including patients older than 80
years.22–24 Quoix et al. reported on seven patients older
than 80 years who were treated with carboplatin and
etoposide among 38 patients older than 70 years with ED.
Four of the seven patients received the six scheduled
cycles, and an objective response was observed in six
patients. The mean survival of the patients (187 days) was
shorter than that overall (237 days), because three cases of
early deaths due to a myocardial infarction, an acute
respiratory distress, and a stroke occurred.22 Other studies
did not stratify the patient population into age groups
including one older than 80 years.23,24 In this study, the
MST and 1-year survival of the treated patients aged 80
years were 13.0 months and 55% in LD and 10.3 months
and 33% in ED, respectively. The results were similar to
those for the treated patients aged 70 to 79 years and were
also comparable to those of younger patients reported
previously.16,17 These findings suggest that carboplatin-
based combination chemotherapies with or without TRT
are feasible for the initial treatment of LD or ED patients
older than 80 years with SCLC, respectively. However, the
results were based entirely on retrospective analyses and
therefore have a high risk of bias. The elderly patients who
received chemotherapy and/or TRT in this study are not
likely to be representative of the whole elderly population.
Actually, none of the patients aged 80 years with PS 4 or
with severe comorbid illness such as respiratory, cardiac,
or renal failure received the treatment for primary tumor.
However, it is noticeable that improved survival was
TABLE 4. Comparison of Adverse Effects of Chemotherapy
Between Age Groups
70–79 yr
(n  32)
80 yr
(n  21) p
Hb
Grade 3 6/32 (19%) 3/21 (14%) 0.67
Grade 4 0/32 (0%) 0/21 (0%)
WBC
Grade 3 7/32 (22%) 8/21 (38%) 0.09
Grade 4 2/32 (6%) 4/21 (19%)
Neu
Grade 3 8/32 (25%) 5/21 (24%) 0.13
Grade 4 6/32 (19%) 9/21 (43%)
Plt
Grade 3 6/32 (19%) 5/21 (24%) 0.69
Grade 4 4/32 (12.5%) 1/21 (5%)
GI
Grade 3 1/32 (3%) 0/21 (0%) 0.41
Grade 4 0/32 (0%) 0/21 (0%)
Other
Grade 3 1/32 (3%) 1/21 (5%) 0.68
Grade 4 1/32 (3%) 0/21 (0%)
Hb, hemoglobin; WBC, white blood cell; Neu, neutrophil; Plt, platelet; GI,
gastrointestinal toxicity.
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observed even in the treated patients older than 80 years
with PS 2 or 3, whereas overall survival was shorter than
those with PS 0 to 1. In addition, no significant influence
of mild to moderate comorbidities on the survival of the
treated patients was observed in this study regardless of
age group and clinical stage. Similar results were reported
in previous studies of elderly patients with SCLC.25,26 The
findings may indicate that SCLC per se rather than comor-
bid disease profoundly affects the prognosis of most el-
derly patients with SCLC. Therefore, anticancer treatments
should not be denied to patients older than 80 years on the
basis of impaired PS or comorbidities, although we should
also keep in mind that elderly patients are less tolerant of
chemotherapy and have a limited life expectancy.
The analysis of prognostic variables in the Cox
model revealed that patients aged 80 years seem to
derive similar benefits from chemotherapy and/or TRT
despite receiving a lower total chemotherapy dose, which
might reflect a relatively low response rate. A similar
relationship between the reduction in dose intensity and
the maintenance of survival in elderly patients with SCLC
compared with younger counterparts was reported previ-
ously. Murray et al. studied the use of two cycles of CAV
with abbreviated concurrent TRT to 30 Gy in patients with
LD-SCLC who were elderly or had poor PS. The MST was
54 weeks, and the 2-year survival rate was 51%.7 Fukuda
et al. conducted a phase 1 study using a lower dose of
carboplatin (AUC 4) combined with etoposide on patients
older than 75 years. The response rate of 69% and the MST
of 16.4 months suggested that the efficacy was not com-
promised by the use of a lower dose of chemotherapy.24 On
the basis of these observations and our results, empiric
dose reductions and omissions to treat elderly patients with
SCLC in this study might not necessarily lead to a worse
therapeutic index. It might result in relatively good sur-
vival rates in this study population despite a response rate
lower than that of previous studies.16,17
Although several previous studies reported increased
toxicity for elderly patients treated with various combina-
tion chemotherapies compared with younger patients, the
incidence of grade 3 and 4 toxicities was not significantly
different between the two age groups in this study.27
Furthermore, treatment-related death seemed to be less
frequent in this study. The reason for the relatively low
incidence of severe toxicity and less frequent treatment-
related death may be frequent dose reductions or omissions
for modest levels of toxicity, perhaps due to a greater
reluctance on the part of both the physician and the older
patient to risk severe toxic effects. However, we could not
find a significant correlation between the total dose deliv-
ered and the incidence of grade 3 and 4 toxicities; there-
fore, personal differences in metabolism, excretion, and
sensitivity to anticancer agents may be rather important
factors for the occurrence of severe toxicities as far as
chemotherapeutic doses were adjusted frequently for
changes in clinical symptoms and laboratory findings.
There were several limitations in this study. First, this
was an observational study and there may have been several
issues with selection bias among the patients who chose
anticancer treatments or best supportive care in each age
group (e.g., less frail and comorbid patients were selected for
active treatment among the patients aged 80 years com-
pared with those aged 70–79 years). Second, the criteria for
dose reductions and omissions varied depending on the phy-
sician in charge. Third, the chemotherapy regimen differed
among study subjects, although more than 80% of the pa-
tients treated underwent a carboplatin-based regimen for
first-line chemotherapy. Fourth, a relatively small number of
patients aged 69 years or younger underwent active treatment
for SCLC during the study period because our hospital
specializes in geriatric medicine. As a result, we were unable
to compare the efficiency and toxicities of treatments for
SCLC with those of younger patients under the same condi-
tions. Fifth, quality of life was not evaluated in this study.
Sixth, substantial evaluations of four patients who received
TRT without chemotherapy and the oldest old patients (85
years) were not carried out because of the low number of
patients.
In conclusion, carboplatin-based combination che-
motherapy with or without TRT is feasible for patients
aged 80 years with SCLC with PS 0 to 1, and even those
with PS 2 to 3 or moderate comorbidities can benefit from
these treatments. However, a dose adjustment system for very
old patients other than glomerular filtration rate and body surface
area seems necessary to maintain the efficacy and improve the
safety profile of combination chemotherapy.
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